News Category
Greenland Mines announced a Q4 2026 biotech spin-off, Nasdaq compliance, and a new acquisition with a high NPV, positioning it as a key rare earths pr...
VERAXA Biotech's appointment of Raju Willener as CFO brings extensive financial leadership to support its capital strategy and oncology pipeline devel...
Scinai Immunotherapeutics strategically pivots its R&D to its NanoAb platform and CDMO business after terminating its PC111 license with PinCell, aimi...
Onco-Innovations Ltd. strengthens its clinical foundation for its lead candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor, through manufactu...
OS Animal Health, a subsidiary of OS Therapies, presented its lead candidate OST-HER2 for canine osteosarcoma at the Disruptive Growth & Life Sciences...
Quantum BioPharma's FDA clearance to test Lucid-MS in a Phase 2 trial marks a pivotal step toward the first therapy that may repair myelin in MS patie...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in a Phase 2 trial for MS marks a potential breakthrough in ...
NanoViricides has registered its Phase II trial for NV-387 Oral Gummies against Ebola in the DRC, marking a critical step in developing an oral antivi...
Greenland Mines (NASDAQ: GRML) announced its Q4 2026 biotech spin-off and completed acquisition of the Sarfartoq project, positioning itself as a focu...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class remyelination agent, marks a pivotal step toward a new approach fo...
Quantum BioPharma's FDA clearance for its Phase 2 trial of Lucid-MS marks a significant step toward a targeted treatment for multiple sclerosis, poten...
The Moody Capital 2026 Disruptive Growth & Life Sciences Conference is strategically timed to address the surge in small-cap activity in life sciences...
The LGL Group's participation in the Moody Capital conference highlights its strategic focus on precision time and frequency technologies and discipli...
Interlink Electronics' participation in the Moody Capital conference underscores its strategic growth initiatives and its leadership in sensors and pr...
Tonix Pharmaceuticals' promotion of Thomas Englese to Chief Commercial Officer underscores the company's strategic focus on expanding commercial opera...
AcroMeta Group has announced a strategic partnership to enter the ambient temperature cellular logistics market, with an option for an exclusive licen...
VERAXA Biotech's appointment of seasoned financial executive Raju Willener as CFO signals a strategic move to bolster its capital markets expertise an...
Onco-Innovations' ONC010, a PNKP inhibitor for cancer, has achieved high-purity API production and is progressing toward a First-in-Human study in Aus...
BioVersys AG will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting its progress in developin...
OS Therapies' participation in the Moody Capital conference underscores a pivotal period as it awaits key regulatory decisions and survival data for i...
A Swiss preclinical study suggests that administering immunotherapy prior to surgical removal of glioblastoma tumors significantly improves treatment ...
Tonix Pharmaceuticals' participation in a major healthcare conference underscores its strategic focus on advancing treatments for fibromyalgia and oth...
NurExone Biologic's participation in the Moody Capital Solutions 2026 conference underscores its strategic focus on advancing exosome-based therapies ...
CNS Pharmaceuticals' Chief Business Officer discusses the company's focus on building a pipeline in oncology and neurology through strategic in-licens...
The launch of SEAM@InnoHK at Hong Kong Science Park marks a significant step in advancing sustainable development, energy, and advanced manufacturing,...
Quantum BioPharma's Lucid-MS drug candidate for progressive multiple sclerosis draws a 'Buy' rating from Rodman & Renshaw, highlighting its potential ...
NanoViricides is progressing its measles treatment NV-387 toward Phase II clinical trials, a critical step given the resurgence of measles cases and t...
TransCode Therapeutics announced that its lead candidate TTX-MC138 demonstrated significant survival benefits in a preclinical model of breast cancer ...
Oragenics provides key updates on its Phase IIa concussion trial, FDA interactions, and NYSE American compliance, highlighting progress and hurdles in...
Creative Biolabs has updated its in vivo CAR-T development portfolio, offering both viral and non-viral approaches to support researchers exploring di...
Lonza's appointment of Samanta Cimitan as its first Chief Commercial Officer underscores the company's commitment to a unified go-to-market approach a...
The NMPA approval allows Heidelberg Pharma and Huadong Medicine to initiate a Phase Ib/II trial of HDP-101 in combination with standard regimens for r...
New peer-reviewed research demonstrates that VolitionRx's Nu.Q NETs H3.1 biomarker independently predicts 28-day mortality and renal replacement thera...
Monod Bio's licensing of its AI-designed LuxSit luciferase and NovoBodies to SignalChem Biotech expands custom assay capabilities, integrating AI-enab...
GeoVax Labs secures immediate funding through a warrant inducement agreement, providing working capital to advance its clinical programs including GEO...
Lakewood-Amedex Biotherapeutics, a clinical-stage biotech developing the novel Bisphosphocin® antimicrobial class, becomes a B2i Digital Featured Comp...
Citius Pharmaceuticals has transitioned to a commercial-stage biopharma with its FDA-approved LYMPHIR generating early revenue, while its late-stage p...
Annovis Bio's corporate update webinar will highlight its Phase 3 Alzheimer's trial data expectations and expanded Parkinson's development, underscori...
A new preprint study demonstrates that a personalized mRNA vaccine derived from a patient's tumor can prevent melanoma recurrence for years, highlight...
An upcoming webinar by Creative Biolabs will discuss modeling T cell dysfunction in the tumor microenvironment, highlighting the importance of metabol...
Synthesis Peptides now provides independent third-party Certificates of Analysis for all 40+ research peptides, enhancing transparency and reliability...
A novel T cell therapy shows promise in treating recurrent glioblastoma, a condition with limited options, potentially transforming care for patients.
The collaboration between VERAXA Biotech and Secarna Pharmaceuticals shows promising early in vitro results for a novel antibody oligonucleotide conju...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate into preclinical development, signaling progress in its oncology pipeline and ...
Scinai Immunotherapeutics reports increased revenue and a bargain purchase gain, while advancing an expanded U.S. clinical manufacturing program that ...
A new composite scoring system, the Seven Up score, may prevent overtreatment of early liver transplant rejection, as most biopsy-detected cases resol...
VERAXA Biotech's favorable Scientific Advice from Germany's Paul-Ehrlich-Institute de-risks the clinical development of its lead BiTAC-TCE therapy, po...
VERAXA Biotech's proprietary BiTAC platform, which uses dual-targeting 'AND-gated' architecture, is progressing through pipeline milestones including ...
